Pharmaceutical methods of treatment with ACAT inhibitors and HMG-CoA reductase inhibitors

ABSTRACT

The present invention is a combination of an ACAT inhibitor, for example, sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl) phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoportein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. Ser. No. 09/051,368 filed Apr. 7, 1998,which is a national filing of PCT/US96/15854 filed Oct. 2, 1986;priority based on Provisional Application No. 60/006,155 filed Nov. 2,1995.

BACKGROUND OF THE INVENTION

The treatment of patients with or at risk of developing ischemicsyndromes with doses of an HMG-CoA reductase inhibitor to lower totaland LDL cholesterol is known. This is done in order to restoreendogenous vascular endothelium-dependent activities including, but notlimited to vasodilatory responses modulating vascular tone and bloodflow, antiadherent properties of the blood vessel wall, andanticoagulation of platelets (International Publication Number WO95/13063).

There is evidence from animal models that compounds which inhibit theenzyme, acyl-coenzyme A:cholesterol acyltransferase (ACAT) will beeffective anti-atherosclerotic agents, (Curr. Med. Chem.,1994;1:204-225). It is well-established that when the majority ofcholesterol in plasma is carried on apolipoprotein B-containinglipoproteins, such as low-density lipoproteins (LDL-C) andvery-low-density lipoproteins (VLDL-C), the risk of coronary arterydisease in man is increased (Circulation, 1990;81:1721-1733).Conversely, high levels of cholesterol carried in high-densitylipoproteins (HDL-C) is protective against coronary artery disease (Am.J. Med., 1977;62:707-714). Thus, a drug which reduces the levels ofatherogenic LDL-C and VLDL-C and elevates levels of protective HDL-Cwill produce a less atherogenic lipoprotein profile and thus abeneficial effect on atherosclerotic disease and its complications. Thisbeneficial effect was demonstrated in man in the Helsinki Heart Studywith the lipid regulator gemfibrozil which decreased LDL-C, increasedHDL-C, and reduced the incidence of coronary artery disease (N. Engl. J.Med., 1987;317:1237-1245).

SUMMARY OF THE INVENTION

We have now shown that a combination of ACAT inhibitor and HMG-CoAreductase inhibitor when administered in a chow/fat diet results in agreater reduction in apo B-containing liproprotein than either alone andthat a normalization of the plasma lipoprotein profile can be achieved.This means the combination treatment results in plasma lipoproteinprofile associated with a decreased risk of coronary artery disease.

We have also shown that a combination of ACAT inhibitors and HMG-CoAreductase inhibitors reduces the cholesteryl esters (CE) enrichment ofpre-existing atherosclerotic lesions to the same extent as the HMG-CoAreductase inhibitor alone but that the histologic character of theatherosclerotic lesions is less complicated. This means that the lesionsare less prone to induce myocardial infarction.

DETAILED DESCRIPTION OF THE INVENTION

The novel method of treatment of this invention and the novelpharmaceutical compositions comprise the administration to a patient atrisk of developing atherosclerosis or a patient in whom the disease hasbeen diagnosed with an ACAT inhibitor and HMG-CoA reductase inhibitorwhich will restore endogenous vascular endothelium-dependent activitiesincluding improving the normal dilation capacity of the endothelium.This method may be used to induce vasodilation to modulate vascular toneand blood flow. Other improvements in vascular endothelium-dependentactivities include decreasing the adherent properties of the bloodvessel walls and decreasing the coagulation of platelets. Suitablesubjects for the method of the present invention include thoseindividuals who currently exhibit symptoms of atherosclerosis and thosewho are at risk of developing various acute ischemic syndromes includingindividuals with high blood pressure, diabetes, or hyperlipidemia, andindividuals who smoke.

The various acute ischemic syndromes that may be treated by the methodof the present invention include: angina pectoris, coronary arterydisease (CAD), hypertension, cerebrovascular accidents, transientischemic attacks, chronic obstructive pulmonary disease, chronic hypoxiclung disease, pulmonary hypertension, renal hypertension, chronic renaldisease, microvascular complications of diabetes, and vaso-occlusivecomplications of sickle cell anemia.

An HMG-CoA reductase inhibitor for use in the novel method may beselected from atorvastatin, lovastatin, simvastatin, pravastatin,fluvastatin, and rivastatin; preferably atorvastatin, lovastatin, orsimvastatin; most preferably atorvastatin.

HMG-CoA reductase inhibitors are known to function asantihypercholesterolemic agents. They reduce hepatic cholesterolbiosynthesis by inhibiting the enzyme HMG-CoA reductase which catalyzesthe early, rate-limiting step in the biosynthesis of cholesterol, theconversion of hydroxymethylglutarate to mevalonate. Known HMG-CoAreductase inhibitors include atorvastatin MEVACOR® (lovastatin), ZOCOR®(simvastatin), PRAVACHOL° (pravastatin), LESCOL® (fluvastatin), andrivastatin. ##STR1##

The doses of HMG-CoA reductase inhibitor contemplated for use in thisinvention are about 5 to 80 mg per day, preferably given in single ordivided doses.

Preferably, the patient is placed on a prudent lipid-lowering dietduring the treatment with the HMG-CoA reductase inhibitors.

Lipid lowering therapy with HMG-CoA reductase inhibitors normalizesvascular function in patients with hypercholesterolemia and/or coronaryartery disease without the requirement for significant regression of theatherosclerotic lesions. The coronary microcirculation, whichdemonstrates significantly impaired endothelium dependent dilatoryresponses in the presence of hypercholesterolemia and atheroscleroticdisease, but is usually free of atheroma, is likely to show markedimprovement demonstrating the ability of lipid lowering therapy to haltthe progression and/or promote regression of atherosclerosis inepicardial arteries in humans.

Atorvastatin is disclosed in U.S. Pat. No. 5,273,995. Related compoundsare disclosed in U.S. Pat. No. 4,681,893.

Lovastatin and related compounds are disclosed in U.S. Pat. No.4,231,938; simvastatin and related compounds are disclosed in U.S. Pat.No. 4,450,171 and U.S. Pat. No. 4,346,227; pravastatin and relatedcompounds are disclosed in U.S. Pat. No. 4,346,227 and fluvastatin andrelated compounds are disclosed in U.S. Pat. No. 4,739,073; rivastatinand related compounds are disclosed in U.S. Pat. Nos. 5,177,080 and5,006,530.

Compounds which effectively inhibit the enzyme, acyl-coenzymeA:cholesterol acyltransferase (ACAT) prevent the intestinal absorptionof dietary cholesterol into the blood stream or the reabsorption ofcholesterol which has been previously released into the intestinethrough the body's own regulatory action. The ACAT inhibiting compoundsprovide treatment of hypercholesterolemia and atherosclerosis. Suchcompounds include, for example, a compound of Formula I ##STR2## or apharmaceutically acceptable salt thereof wherein: X and Y are selectedfrom oxygen, sulfur and (CR'R")_(n')

wherein n is an integer of from 1 to 4 and R' and R" are eachindependently hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy,cycloalkyl, phenyl optionally substituted or R' and R" together form aspirocycloalkyl or a carbonyl;

with the proviso at least one of X and Y is (CR'R")_(n) and with thefurther proviso when X and Y are both (CR'R")_(n) and R' and R" arehydrogen and n is one, R₁ and R₂ are aryl;

R is hydrogen, a straight or branched alkyl of from

1 to 8 carbon atoms or benzyl;

R₁ and R₂ are each independently selected from

(a) phenyl or phenoxy each of which is unsubstituted or is substitutedwith 1 to 5 substituents selected from

phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight orbranched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight orbranched;

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

--COOH,

--COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight orbranched,

--(CH₂)_(p) NR₃ R₄ wherein p is zero or one, and each of R₃ and R₄ isselected from hydrogen or a straight or branched alkyl group having 1 to4 carbon atoms;

(b) 1- or 2-naphthyl unsubstituted or substituted with from 1 to 3substituents selected from

phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight orbranched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight orbranched;

hydroxy,

phenoxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

--COOH,

--COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight orbranched,

--(CH₂)_(p) NR₃ R₄ wherein p, R₃ and R₄ have the meanings defined above;

(c) arylalkyl;

(d) a straight or branched alkyl chain having from 1 to 20 carbon atomsand which is saturated or contains from 1 to 3 double bonds; or

(e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety hasfrom 3 to 6 carbon atoms; with the provisos:

(i) where X is (CH₂)_(n), Y is oxygen, and R₁ is a substituted phenyl,then R₂ is a substituted phenyl;

(ii) where Y is oxygen, X is (CH₂)_(n), R² is phenyl or naphthyl, thenR¹ is not a straight or branched alkyl chain; and

(iii) the following compounds are excluded:

    ______________________________________                                        X         Y     R         R.sub.1   R.sub.2                                   ______________________________________                                        CH.sub.2  O     H         (CH.sub.2).sub.2 CH.sub.3                                                               Ph                                          CH.sub.2 O H CH.sub.3 Ph                                                       - CH.sub.2 O H                                                             Pr                                    iSTR3##                                 ______________________________________                                    

The ACAT inhibitor for use in the novel method may be selected from anyeffective compound, especially compounds of Formula I above, especiallysulfamic acid, [[2,4,6-tris(methylethyl)-phenyl]acetyl]-,2,6-bis[(1-methylethyl)phenyl ester; 2,6-bis(1-methylethyl)phenyl-[[2,6-bis(1-methylethyl)-phenyl]sulfonyl]carbamate monosodiumsalt; N-(2,6-di-isopropyl-phenyl)-2-phenyl-malonamic acid dodecyl ester;N-(2,6-diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide;2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-docecanamide; andN-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethyl-amino)phenyl]cyclopentyl]methyl ureamonohydrochloride.

The doses of ACAT inhibitor contemplated for use in this invention anabout 50 to 1500 mg per day, preferably given in single or divideddoses.

One especially useful ACAT inhibitor is 2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate disclosed in U.S.patent application Ser. No. 08/223,932 filed Apr. 13, 1994, which ishereby incorporated by reference.

Other ACAT inhibitors are2,6-bis-(1-methylethyl)-phenyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]-carbamatemonosodium salt; and similar compounds are disclosed in U.S. Pat. No.5,245,068; N-(2,6-diisopropyl-phenyl)-2-phenyl-malonamic acid dodecylester; and similar compounds are disclosed in U.S. Pat. No. 5,420,339;N-(2,6-diiso-propyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide;and similar compounds are disclosed in U.S. Pat. No. 5,366,987 anddivisional U.S. Pat. No. 5,441,975;N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclo-penty]methyl]urea monohydrochloride disclosed in U.S. Pat. No.5,015,644 and 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl) docecanamide andsimilar compounds disclosed in U.S. Pat. No. 4,716,175.

The lipid modifying and antiatherosclerotic action of2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate,atorvastatin, and the combination of both compounds was assessed in arabbit model of atherosclerosis in which the combination ofhypercholesterolemia and chronic endothelial denudation of theiliac-femoral artery promotes lesion development.

The model of atherosclerosis consists of a lesion induction phase of 15weeks followed by an 8-week drug intervention phase. A main feature ofthe protocol is that after 9 weeks of a 0.5% cholesterol (C), 3% peanut(PNO), 3% coconut (CNO) oil diet plasma, cholesterol levels arenormalized by feeding a 0% C, 3% PNO, 3% CNO diet prior to drugadministration. The animals are randomized based on their mean plasmatotal cholesterol levels and administered the 0% C, 3% PNO, 3% CNO dieteither alone or containingN-(2,6-diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamideat 10 mg/kg, atorvastatin at 5 mg/kg, orN-(2,6-diiso-propyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide+atorvastatin at 10+5 mg/kg for the next 8 weeks.

Relative to the untreated, cholesterol-fed control, plasma totalcholesterol levels were unchanged by2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamatebut reduced 43% and 67% with atorvastatin and2,6-bis(1-methylethyl)-phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-sulfamate+atorvastatin, respectively. Associated with the changes in plasma totalcholesterol were marked alterations in the plasma lipoproteindistribution.2,6-Bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamatereduced % VLDL-cholesterol (VLDL-C) and increased % LDL-cholesterol(LDL-C); atorvastatin had limited effect; and upon combination treatment% VLDL-C and % LDL-C were reduced, and % HDL-cholesterol was increased.

Results are summarized in Table I below.

                  TABLE I                                                         ______________________________________                                        Lipoprotein Distribution Expressed as                                           Percent of Total Plasma Cholesterol                                                         VLDL      LDL     HDL                                         ______________________________________                                        Progression Control                                                                           16        60      24                                            2,6-bis(1-methylethyl)- 5 73 22                                               phenyl[[2,4,6-tris(1-                                                         methylethyl)phenyl]-                                                          acetyl]sulfamate (10 mg/kg)                                                   Atorvastatin (5 mg/kg) 14 48 38                                               2,6-bis(1-methylethyl)- 4 35 60                                               phenyl[[2,4,6-tris(1-                                                         methylethyl)phenyl]-                                                          acetyl]sulfamate +                                                            Atorvastatin (10 + 5 mg/kg)                                                 ______________________________________                                    

Analysis of the vascular cholesteryl ester (CE) enrichment, incidence ofcomplex atherosclerotic lesions, gross extent of thoracic aorticatherosclerosis, and size and composition of the iliac-femoral lesionhave also been performed.2,6-Bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)-phenyl]acetyl]sulfamatehad no effect on the CE enrichment of the thoracic aorta andiliac-femoral artery and on the gross extent of lesion coverage in thethoracic aorta; however, the incidence of complex fibrous plaques withinthe iliac-femoral artery was reduced from 50% to 14%. Atorvastatinreduced the CE enrichment of both vascular regions by 27% to 41% withoutchanging the gross extent of thoracic lesions and incidence of fibrousplaques.2,6-Bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)-phenyl]acetyl]sulfamate+atorvastatin had no effect on the CE enrichment of the thoracic aortaand gross extent of thoracic aortic lesions; however, the iliac-femoralCE content was reduced 23% and incidence of fibrous plaques wasdecreased to 17%. Comparison of the data relative to the time zerocontrol, i.e., prior to drug administration, atorvastatin alone and incombination with2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamatesignificantly reduced the CE enrichment of the iliac-femoral artery.Morphometric analysis of the iliac-femoral artery revealed thatatorvastatin reduced the lesion size, while the combination ofatorvastatin and2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)-phenyl]acetyl]sulfamatesignificantly decreased the monocyte-macrophage content of the lesionwithout changing lesion size.2,6-Bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)-phenyl]acetyl]sulfamatealone had no effect on the iliac-femoral lesion size or composition.

Therefore, it is clear that a combination ofN-(2,6-diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamideand atorvastatin administered in a chow/fat diet results in a greaterreduction in plasma apo B-containing lipoprotein than either alone andthat a normalization of the plasma lipoprotein distribution is achieved.Atorvastatin not only blunts the cholesteryl ester enrichment of thevasculature but also decrease the lipid enrichment of a pre-existingatherosclerotic lesion. 2,6-Bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)-phenyl]acetyl]sulfamate +atorvastatin reduces theCE enrichment of pre-existing atherosclerotic lesions to the same extentas atorvastatin alone, but the atherosclerotic lesions are lesscomplicated with respect to their histologic character.

For preparing the pharmaceutical compositions from the compounds of thisinvention, inert, pharmaceutically acceptable carriers can be eithersolid or liquid. Solid form preparations include powders, tablets,dispersible granules, capsules, and cachets.

A solid carrier can be one or more substances which may also act asdiluents, flavoring agents, solubilizers, lubricants, suspending agents,binders, or tablet disintegrating agents; it can also be anencapsulating material.

In powders, the carrier is a finely divided solid which is in a mixturewith the finely divided active component. In tablets, the activecomponent is mixed with the carrier having the necessary bindingproperties in suitable proportions and compacted in the shape and sizedesired.

Powders and tablets preferably contain between about 5% to about 70% byweight of the active ingredient. Suitable carriers are magnesiumdicarbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin,starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, alow-melting wax, cocoa butter, and the like.

The term "preparation" is intended to include the formulation of theactive compound with encapsulating material as a carrier providing acapsule in which the active component (with or without other carriers)is surrounded by a carrier, which is thus in association with it. In asimilar manner cachets or transdermal systems are also included.

Tablets, powders, cachets, and capsules can be used as solid dosageforms suitable for oral administration.

Liquid form preparations include solutions, suspensions, or emulsionssuitable for oral administration. Aqueous solutions for oraladministration can be prepared by dissolving the active compound inwater and adding suitable flavorants, coloring agents, stabilizers, andthickening agents as desired. Aqueous suspensions for oral use can bemade by dispersing the finely divided active component in water togetherwith a viscous material such as natural or synthetic gums, resins,methyl cellulose, sodium carboxymethylcellulose, and other suspendingagents known to the pharmaceutical formulation art.

Preferably, the pharmaceutical preparation is in unit dosage form. Insuch form, the preparation is divided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation containing discrete quantities of thepreparation, for example, packeted tablets, capsules, and powders invials or ampoules. The unit dosage form can also be a capsule, cachet,or tablet itself, or it can be the appropriate number of these packagedforms.

The dosage forms are well within the skill of a physician who will befamiliar with such factors as time of day and other pertinentconsiderations.

What is claimed is:
 1. A method of restoring endogenous vascularendothelium-dependent activities selected from preventing coagulation ofplatelets, decreasing the adherent properties of blood vessel walls, andinducing vasodilation to modulate vascular tone and blood flow in amammal in need thereof which comprises administering a therapeuticallyeffective amount of one or more ACAT inhibiting compounds and one ormore HMG-CoA reductase inhibitors.
 2. A method according to claim 1wherein the ACAT inhibitor is selected from: sulfamic acid,[[2,4,6-tris(methylethyl)phenyl]acetyl]-, 2,6-bis[(1-methylethyl)phenylester;2,6-bis(1-methylethyl)phenyl-[[2,6-bis(1-methylethyl)-phenyl]sulfonyl]carbamatemonosodium salt; N-(2,6-diisopropyl-phenyl)-2-phenyl-malonamic aciddodecyl ester; 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)docecanamide; andN-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]-cyclopentyl]methylurea monohydrochloride; and the HMG-CoA reductase inhibitor is one ormore compounds selected from rivastatin, lovastatin, simvastatin,pravastatin, fluvastatin, and atorvastatin.
 3. A method according toclaim 1 wherein the ACAT inhibitors2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate,and the HMG-CoA reductase inhibitor is one or more compounds selectedfrom rivastatin, lovastatin, simvastatin, pravastatin, fluvastatin, andatorvastatin.
 4. A method according to claim 1 wherein2,6-bis(1-methylethyl)phenyl[[2,4,6-tris-(1-methylethyl)phenyl]acetyl]sulfamateand the HMG-CoA reductase inhibitor is selected from simvastatin andatorvastatin.
 5. A method according to claim 1 wherein thetherapeutically effective dose of ACAT inhibitor is 50 to 1500 mg perday, and the therapeutically effective dose of HMG-CoA reductaseinhibitor is about 5 to about 80 mg/day.
 6. A method according to claim1 to prevent coagulation of platelets.
 7. A method according to claim 1to decrease the adherent properties of blood vessel walls.
 8. A methodaccording to claim 1 to induce vasodilation to modulate vascular toneand blood flow.
 9. A method of preventing or treating diseasesassociated with endothelial dysfunction selected from: angina pectoris,myocardial infarctions, coronary artery disease, hypertension,cerebrovascular accidents, transient ischemic attacks, chronicobstructive pulmonary disease, chronic hypoxic lung disease, pulmonaryhypertension, renal hypertension, chronic renal disease, microvascularcomplications of diabetes, and vaso-occlusive complications of sicklecell anemia, preventing coagulation of platelets, decreasing theadherent properties of blood vessel walls, and inducing vasodilation tomodulate vascular tone and blood flow in a mammal in need thereof whichcomprises administering a therapeutically effective amount of one ormore ACAT inhibiting compounds and one or more HMG-CoA reductaseinhibitors.
 10. A method according to claim 9 which comprises sulfamicacid, [[2,4,6-tris(methylethyl)phenyl]acetyl]-,2,6-bis[(1-methylethyl)phenyl ester;2,6-bis(1-methyl-ethyl)phenyl[[2,6-bis(1-methylethyl)phenyl]sulfonyl]carbamatemonosodium salt; N-(2,6-diisopropyl-phenyl)-2-phenyl-malonamic aciddodecyl-ester;5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-ylbenzo[6]-thiopheno-2-carboxamidemonosodium salt; 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-docecanamide;andN-[2,6-bis(1-methylethyl)-phenyl]-N'-[[1-[4-(dimethylamino)phenyl]-cyclopentyl]methylurea monohydrochloride; and the HMG-CoA reductase inhibitor is one ormore compounds selected from rivastatin, lovastatin, simvastatin,pravastatin, fluvastatin, and atorvastatin.
 11. A method according toclaim 9 which comprises2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]-acetyl]sulfamate,N-(2,6-diisopropyl-phenyl)-2-phenyl-malonamic acid dodecyl- ester, andN-(2,6-diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide;and the HMG-CoA reductase inhibitor is one or more compounds selectedfrom rivastatin, lovastatin, simvastatin, pravastatin, fluvastatin, andatorvastatin.